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TO THE EDITOR
We are pleased at the interest that Pan
et al. (2011) have shown in our paper
‘‘IL-18 Downregulates Collagen Pro-
duction in Human Dermal Fibroblasts
via the ERK Pathway’’ (Kim et al.,
2010). We thank them for giving us
this opportunity to discuss IL-18 in
more detail.
Although the pathogenesis of sys-
temic sclerosis (SSc) remains unknown,
cytokine production and release are
key events in the disease, characterized
by chronic inflammation and fibrosis
(Baraut et al., 2010). IL-18 is a unique
cytokine that has a critical role in
various immunological responses.
Recent data shed more light on the
complex and paradoxical role of IL-18
in various disease processes, including
fibrosis.
So far, only four studies (including
case reports) have been conducted on
SSc in relation to IL-18, including ours.
Mosaad et al. (2003) have identified a
significant positive correlation between
serum concentration of IL-18 and the
clinical grades of immune rheumatic
diseases, mostly systemic lupus erythe-
matosus and rheumatoid arthritis. As
only a small number of scleroderma
patients were included, we consider it
a bit hasty to conclude that ‘‘serum IL-
18 levels in SSc patients were signifi-
cantly higher than that in a control
group, and there was a significant
positive correlation between the levels
of IL-18 and clinical grades of SSc’’, as
mentioned by Pan et al. (2011). Scala
et al. (2004) evaluated the expression of
various cytokines and chemokines in
patients affected by SSc, using different
biological specimens such as serum
and supernatants from activated peri-
pheral blood mononuclear cells
(PBMCs) and T-cell lines. IL-18 produc-
tion from PBMC was significantly high-
er in SSc patients compared with the
control group, but there was no differ-
ence in the amount of IL-18 in serum
samples and T-cell supernatants. PBMC
IL-18 was significantly lower in SSc
patients with kidney involvement. The
findings did not show a definite trend,
and Scala et al. (2004) point out that
as patients included in the study had
well-established disease, it would be
necessary to perform longitudinal
studies to evaluate the cytokine profile
in early stages, when the disease is
generally much more immunologically
active. Overall, no definite conclusion
on the role of IL-18 in SSc could be
drawn from the two papers.
As mentioned by Pan et al. (2011), a
number of studies have attempted to
identify the role of IL-18 in organ
fibrosis. Several recent studies have
illustrated IL-18 as a fibrogenic cyto-
kine. In a study by Hoshino et al.
(2009), enhanced expression of both
IL-18 and IL-18R-a was observed in the
lungs of five patients with bleomycin
(BLM)-induced lung injury. Zhang et al.
(2007) showed that hepatic fibrosis by
repeated injection of concanavalin-A
in the mouse model was aggravated by
IL-18 and blocked by anti-IL-18. Reddy
et al. (2008) demonstrated IL-18 to
stimulate fibronectin expression in pri-
mary human cardiac fibroblasts via
phosphoinositide 3-kinase-Akt-depen-
dent NF-kB activation.
On the other hand, a number of
reports have shown IL-18 to reverse
fibrosis. In a study conducted by Zhang
et al. (2001), mice intrasplenically
transplanted with IL-18 gene-modified
hepatocytes developed much less
hepatic fibrosis 20 weeks after Schisto-
soma japonicum infection. Similarly,
Nakatani-Okuda et al. (2005) showed
that IL-18 can protect against BLM-
induced lung injury in mice.
IL-18 is a unique cytokine with the
capacity to induce Th1 or Th2 polariza-
tion, depending on the immunological
context. IL-18 expression and effecter
function have now been described in
various inflammatory diseases across a
broad range of tissues, and recent evi-
dence supports the concept of the dual
role of IL-18 in inflammation, includ-
ing graft-versus-host disease, sepsis, and
tumor progression (Reddy et al., 2004;
Park et al., 2007).
There is evidence that a balance
between Th1/Th2 is closely involved in
the development of fibrosis, where Th1
cytokines drive the early inflammation
and Th2 cytokine response, with the
production of IL-4, IL-10, and tissue
growth factor-b, leading to fibrosis. Over-
all, the dual effect of IL-18 as a profibrotic
or antifibrotic mediator seems to depend
on the induction of Th1 or Th2 cytokines,
where discrepancies between previous
studies are likely the result of the
differences in the models and the meth-
od, timing, and dosage of IL-18 admin-
istration, and the age of the animals.
Our data (Kim et al., 2010) suggested
that IL-18 may exert antifibrotic
activities in dermal fibroblasts in vitro.
However, further delineation of the
in vivo regulation of IL-18 synthesis,
signaling, and biological effects of differ-
ent cellular subsets in the context of
IL-18-binding protein and other native
inhibitors, and its position in the func-
tional hierarchy of pro- and anti-inflam-
matory cytokines remain to be fully
elucidated. The genetic–spatial–temporal
interplay of IL-18 among a vast array of
inflammatory mediators, rather than a
simple increase or decrease in its
expression, is required to better under-
stand the role of IL-18 in fibrosis.
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TO THE EDITOR
The aberrant activation of the PI3K/AKT
pathway in melanoma is known to be
caused by genomic deletion, promoter
methylation, or loss-of-function muta-
tions of phosphatase and tensin homo-
log on chromosome 10 (PTEN; see
Madhunapantula and Robertson (2009)
for a review).
More recently, PTEN protein abun-
dance was shown to be decreased at
the posttranscriptional level by a com-
plex microRNA network (He, 2010).
The processed pseudogene of PTEN,
PTENP1, is a modulator of the interac-
tion between PTEN mRNA and PTEN-
targeting microRNAs (Poliseno et al.,
2010). PTENP1 shows extensive se-
quence similarity with PTEN. The high
level of conservation in the most up-
stream region of the 30UTR allows
PTENP1 mRNA to be bound by many
of the microRNA families that bind
PTEN mRNA (Figure 1 and Supplemen-
tal Text S1 online). Therefore, PTENP1
can protect PTEN from microRNA-
mediated downregulation. Consistent
with its activity as a decoy for PTEN-
targeting microRNAs, PTENP1 is a bona
fide tumor suppressor gene that causes
growth inhibition in prostate cancer
cells and undergoes deletion in various
human malignancies (Poliseno et al,
2010).
As recently pointed out (Chen, 2010),
the posttranscriptional regulation of
PTEN levels in melanoma has not been
studied yet and the status of PTENP1 on
9p13 is unknown. Here, we report the
analysis of PTENP1 locus in human
melanoma cell lines and tissues (Sup-
plementary Table S1 online). We also
analyze the relationship between the
following: (1) PTENP1 deletion and
CDKN2A deletion, as they are located
B20cM apart on chromosome 9p
(Bennett, 2008); (2) PTENP1 deletion
and PTEN deletion, as 9p and 10q losses
often coexist in melanoma (Indsto et al.,
1998); (3) PTENP1 deletion and BRAF/
NRAS mutation, as the combination of
mutated BRAF (but not NRAS) and loss
of PTEN expression is a common event
in human melanoma (Tsao et al., 2004).
Our genomic analysis revealed par-
tial deletion of PTENP1 locus in 14.3%
of the cell lines tested (Figure 2a). In
addition, PTENP1 was found to be
deleted in 20.9% of melanoma tissues
(eight partial and one complete dele-
tion; Figure 2b). These results illus-
trate that PTENP1 is under selective
pressure to undergo copy number losses
(Poliseno et al., 2010). The average
PTEN expression level in the 9 samples
with either partial or complete deletion
of PTENP1 (P5, P9, P11, P12, P20, M1,
M9, M14, and M16) was lower
than that in the remaining 34 samples
without any PTENP1 deletion (5.22±
2.30 (N¼ 9) vs. 20.59±3.98 (N¼ 34),
P¼0.06), confirming the protective
effect of PTENP1 on PTEN levels
(Poliseno et al., 2010).
The details of the analyses of
CDKN2A deletion, PTEN deletion, and
BRAF and NRAS mutation in the human
melanoma cell lines and tissues are
provided in Supplemental Text S2 online
(Supplementary Figures S1, S2, and
S3 online).
We observed that the partial or com-
plete deletion of PTENP1 is always
concomitant with the partial or complete
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